Response to budesonide formoterol and omalizumab combination therapy: a retrospective study in adults with allergic asthma

Abstract

Abstract Background Omalizumab is an anti-IgE humanised monoclonal antibody marketed in China for the conventional treatment of poorly controlled moderate to severe allergic asthma. Numerous clinical trials have demonstrated the effectiveness of omalizumab, but data from studies in actual clinical treatment are still relatively limited. Methods Data were collected on 32 patients who met the inclusion criteria. Clinical characteristics before and after omalizumab treatment were collected to analyze the relationship between changes in serum total IgE levels and peripheral blood EOS levels, FEV1, PEF, OCS dosage, ATC score and number of acute exacerbations and treatment response, to observe the efficacy of omalizumab treatment and to investigate whether baseline clinical characteristics such as serum total IgE and EOS levels could predict treatment response. Results Using the ACT score as an evaluation, 68.75% of patients benefited from omalizumab treatment at the end of 16 weeks. Response group has a reduction in OCS dosage (P values 0.026, 0.039), a significant reduction in ACT scores (both P < 0.001) and a reduction in the number of acute exacerbations (P 0.034, 0.025 respectively) after omalizumab treatment. The Binary logistics analysis of factors affecting the effectiveness of omalizumab in the treatment of allergic asthma were total serum IgE and the presence of comorbidities (p-values of 0.039 and 0.046 respectively). Conclusions Omalizumab combined with budesonide formoterol was effective after 16 weeks of treatment. Serum IgE levels and the presence of comorbidities predicted response to omalizumab treatment.